Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway.
Jun J YangPublished in: British journal of cancer (2024)
The "undruggable" MYC oncoproteins are deregulated in 70% human cancers. The approval of DFMO, an irreversible inhibitor of ornithine oxidase (ODC1) that is a direct transcriptional target of MYC, demonstrates that patients can benefit from targeting MYC activity via an indirect approach. However, the mechanism of action of DFMO needs further studies to understand how it works in post-immunotherapy neuroblastomas. Efforts to develop a more potent and safer drug to block MYC function will continue despite challenges.
Keyphrases
- transcription factor
- end stage renal disease
- ejection fraction
- newly diagnosed
- prognostic factors
- gene expression
- peritoneal dialysis
- endothelial cells
- patient reported outcomes
- emergency department
- young adults
- oxidative stress
- quality improvement
- cancer therapy
- electronic health record
- drug induced
- childhood cancer